FlightSafety International Announces Major Expansion at Farnborough Airport
7.5.2025 17:56:00 CEST | Business Wire | Press Release
FlightSafety International (FSI), a global leader in aviation training, is pleased to announce the expansion of its facilities at Farnborough Airport, the home of British aviation and Europe’s leading airport for premium air travel connectivity, highlighting its commitment to enhancing aviation safety and training excellence in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506583636/en/
Rendering: arriving at FlightSafety International
The new FSI centre is expected to open in the second quarter of 2027. Lease terms have been finalised and the planning application was submitted in January. Construction is scheduled to start in late 2025 and finish by early 2027.
FSI has operated a training centre at Farnborough Airport since 2004. The new facilities will boost training capacity by 40-50%, enabling more aviation professionals access to FSI's world-class training programmes. The current facility is 4,680 square metres. It features 11 advanced simulators and training for over 14 aircraft types, including both fixed-wing and rotary-wing models, and trains approximately 3,500 clients each year. The expansion will add 0.7 hectares to relocate parking and create a 4,680-square-metre space for six full-flight simulators, 10 lower-level training devices, and 19 classrooms.
FSI employs over 1,800 professional instructors globally, delivering more than 1.4 million hours of training annually. The expansion will add more than 60 new jobs, including 40 instructors, eight simulator technicians, six customer support specialists, three administrative staff, and five programme managers to the Farnborough location.
“This expansion at Farnborough Airport represents a significant milestone in our commitment to enhancing aviation training across Europe,” said Ben Carter, Executive Vice President, Learning Center Operations. “By increasing our capacity and capabilities, we aim to not only meet the growing demand for high-quality flight training but also reinforce our dedication to improving aviation safety globally.”
By expanding its Farnborough facility, FSI aims to reduce the need for European customers to travel to the U.S. for training. The project will positively impact the local economy as clients often use nearby hotels, bed and breakfasts, and serviced apartments. The expansion is expected to generate an additional 9,000 hotel nights annually, benefiting local businesses, including food, entertainment, and shopping.
Farnborough Airport is Europe’s leading business aviation airport, the birthplace of British aviation and the first business aviation airport to achieve carbon neutrality. It plays an essential role in supporting economic growth, contributing £1.9 billion in Gross Value Added (GVA) to the UK economy annually.
Simon Geere, CEO at Farnborough Airport said, “We are proud to support FlightSafety International’s continued growth. The expansion of FSI’s facilities at Farnborough Airport will create further local jobs, generate inward investment, increase international business traffic, and ensure that Farnborough continues to be at the forefront of aviation innovation and safety for years to come.”
For more information, please contact:
FlightSafety International Press Office
fsipress@apcoworldwide.com
About FlightSafety International
FlightSafety International is the world’s preeminent professional aviation training company and supplier of flight simulators, visual systems, and displays to educational, commercial, government, and military organizations. The company elevates safety standards across the aviation industry through rigorous training for pilots, technicians, and other professionals from 167 countries and independent territories. FlightSafety operates the world’s largest fleet of advanced full-flight simulators at learning centres and training locations in the United States, Canada, France, the United Kingdom, and Singapore. For more information, please visit FlightSafety.com, and follow @FlightSafetyInt on Facebook, Instagram, and LinkedIn.
About Farnborough Airport
Farnborough Airport is Europe’s leading business aviation airport, the Birthplace of British aviation and first business aviation airport to achieve carbon neutrality. According to a study by CBI Economics, approximately 80% of the flying activity from Farnborough Airport relates to either directly or indirectly to supporting UK business and inward investment, contributing £1.9 billion of Gross Value Added (GVA) to the UK economy every year.
The most modern airport of its kind and the largest business aviation airport in the UK, Farnborough Airport offers five-star service, exclusivity, and privacy within easy reach of London, making it the premium choice for those looking to travel safely, flexibly, and efficiently. With health and wellbeing more important than ever, business aviation is fast becoming a preferred option for those wishing to travel with complete assurance. From the moment passengers arrive at Farnborough, they can expect exceptional service at every point in their journey through the airport, including a dedicated concierge service on hand for every need. The award-winning terminal offers multiple lounges, private meeting rooms and refreshments. Passengers can also travel with their dogs or cats as Farnborough offers a Pet Travel Scheme with an on-site vet to allow beloved companions to travel safely around the world.
For more information, please contact the Farnborough Airport Communications team via enquiries@farnboroughairport.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506583636/en/
Contacts
For media enquiries please contact:
FSI Press Office
fsipress@apcoworldwide.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom